MA5-11986

antibody from Invitrogen Antibodies

Targeting: KRT7 CK7, K2C7, K7, SCL

Provider product page for MA5-11986

Western blot

Antibody data

Antibody Data
Antigen structure
References [55]
Comments [0]
Validations
Western blot [2]
Immunocytochemistry [1]
Immunohistochemistry [1]
Flow cytometry [1]
Other assay [2]

Submit

Product number: MA5-11986 - Provider product page
Provider: Invitrogen Antibodies
Product name: Cytokeratin 7 Monoclonal Antibody (OV-TL 12/30)
Antibody type: Monoclonal
Antigen: Other
Description: MA5-11986 targets Cytokeratin 7 in IHC (P) applications and shows reactivity with Human samples.
Antibody clone number: OV-TL 12/30
Concentration: 0.2 mg/mL

KRT7 protein structure - MA5-11986 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis was performed on whole cell extracts (30 µg lysate) of A549 (Lane 1), HeLa (Lane 2), A-431 (Lane 3), PC-3 (Lane 4), and SK-OV-3 (Lane 5). The blots were probed with Anti-Cytokeratin 7 Mouse Monoclonal Antibody (Product # MA5-11986, 2 µg/mL) and detected by chemiluminescence using Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjµgate (Product # A28177, 0.4 µg/mL, 1:2500 dilution). A 50 kDa band corresponding to Cytokeratin 7 was observed across the cell lines tested. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 10 % Bis-Tris gel (Product # NP0302BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with iBlot® 2 Dry Blotting System (Product # IB21001). The membrane was probed with the relevant primary and secondary Antibody following blocking with 5% skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot was performed using Cytokeratin 7 Monoclonal Antibody (OV-TL 12/30) (Product # MA5-11986) and a 51 kDa band corresponding to KRT-7 was observed in positive cell lines HeLa, A549, OVCAR-3 and not in negative cell lines such as A431 and SK-OV-3 as mentioned in literature. Membrane enriched extracts (30 µg lysate) of HeLa (Lane 1), A549 (Lane 2), OVCAR-3 (Lane 3), A431 (Lane 4) and SK-OV-3 (Lane 5) were electrophoresed using NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX). Resolved proteins were then transferred onto a nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with the primary antibody (1:1000 dilution) and detected by chemiluminescence with Goat anti-Mouse IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A28177, 1:4000 dilution) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using Novex® ECL Chemiluminescent Substrate Reagent Kit (Product # WP20005).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Hepatic expression of FGF19 in biliary atresia was found in hepatocytes but not cholangiocytes at time of KPE. (a, b) FGF19 and CK7 staining in two consecutive sections at 10x magnification. FGF19 was found in areas of hepatocytes but not cholangiocytes Squares in (a) represents magnified areas in (c-e). FGF19 staining at 40x magnification. FGF19 was found in both intact hepatocytes and in giant cells as seen in the upper left corner of (e).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2. Alagille syndrome human and murine bile ducts end abruptly. ( A ) Jag1 Ndr/Ndr BDs (right panel) terminated randomly and facing toward the hilum (blue arrowheads). ( B ) 2D histological consecutive liver sections confirmed abruptly terminating BDs in Jag1 Ndr/Ndr liver. Black arrowhead depicts lumenized well-formed BD that ended in the following sections (blue arrowhead). ( C ) BDs in patients with severe ALGS (top panel) or mild ALGS (bottom panel) terminate abruptly (blue arrowhead) in consecutive liver histological sections. Scale bars ( A ) 500 um, (B left panels), ( C ) 50 um, (B boxed region) 20 um. ALGS, Alagille syndrome; BD, bile duct; CK, cytokeratin; H, hilar; P, peripheral. PV, portal vein. Figure 2--figure supplement 1. Overview of liver samples from patients with Alagille syndrome stained for CK7. ( A ) 2D liver section from a healthy control shows a round lumenized BD adjacent to the portal vein. ( B ) Representative 2D histological sections from four patients with severe ALGS. The age at liver transplantation and total bilirubin levels are above each panel. ( C ) Representative 2D histological sections from six patients with mild ALGS. The age at liver biopsy and total bilirubin levels are above each panel. ( D ) 2D histological sections of liver biopsies from patient #5 with mild ALGS showing phenotypic recovery with no bile ducts, but some CK+ hepatocytes at 2.5 months, numerous CK7+ hepatocytes at 1 year and 4 months, and lumenized CK7+ bile ducts